ClinConnect ClinConnect Logo
Search / Trial NCT07024927

Complex Arrhythmia Registry

Launched by BEIJING ANZHEN HOSPITAL · Jun 9, 2025

Trial Information

Current as of July 01, 2025

Not yet recruiting

Keywords

Atrial Fibrillation Ventricular Tachycardia Ablation Registry Study

ClinConnect Summary

This clinical trial, called the Complex Arrhythmia Registry, is studying how well and how safely a treatment called catheter ablation works over the long term for people with two types of heart rhythm problems: atrial fibrillation (AF) and ventricular tachycardia (VT). Catheter ablation is a procedure that uses special tools guided by 3D imaging to treat irregular heartbeats. This study will take place at multiple centers in China and will observe patients after their first catheter ablation procedure to better understand outcomes in real-world settings.

People who might be eligible to join are adults aged 18 and older who have been diagnosed with either AF or VT and are scheduled for their first catheter ablation using a 3D mapping system. For those with AF, this includes patients with different types of this irregular heartbeat, while for those with VT, eligibility includes having VT linked to specific heart conditions like heart disease or cardiomyopathy. Participants will need to agree to take part in the study and complete follow-up visits as required. The study is not yet recruiting, and certain health conditions like severe infections, recent heart attacks, or participation in other conflicting studies may exclude someone from joining. If enrolled, patients can expect their treatment and progress to be carefully tracked over time to help doctors learn more about how this procedure works in everyday practice.

Gender

ALL

Eligibility criteria

  • 1. Atrial Fibrillation (AF) Cohort:
  • * Inclusion Criteria (Patients must meet ALL of the following criteria):
  • 1. Age ≥ 18 years.
  • 2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
  • 3. Scheduled to undergo first-time catheter ablation for AF.
  • 4. Procedure to be performed using a 3D mapping system.
  • 5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
  • * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):
  • 1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
  • 2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
  • 3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
  • 4. Severe active infection (e.g., septic shock, sepsis).
  • 5. Contraindications to anticoagulation therapy.
  • 6. Current participation in another interventional clinical trial that may confound the results of this study.
  • 7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
  • 2. Ventricular Tachycardia (VT) Cohort
  • * Inclusion Criteria (Patients must meet ALL of the following criteria):
  • 1. Age ≥ 18 years.
  • 2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:
  • 3. Ischemic heart disease (e.g., prior MI, coronary artery disease).
  • 4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).
  • 5. Scheduled to undergo first-time catheter ablation for VT.
  • 6. Procedure to be performed using a 3D mapping system.
  • 7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
  • * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):
  • 1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).
  • 2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).
  • 3. Cardiac surgery within 60 days prior to the planned ablation procedure.
  • 4. Severe coagulopathy (e.g., platelet count \< 50 x 10⁹/L, disseminated intravascular coagulation (DIC)).
  • 5. Severe heart failure with left ventricular ejection fraction (LVEF) \< 20%.
  • 6. Severe active infection (e.g., septic shock, sepsis).
  • 7. Current participation in another interventional clinical trial that may confound the results of this study.
  • 8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.

About Beijing Anzhen Hospital

Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.

Locations

Beijing, , China

Patients applied

0 patients applied

Trial Officials

Deyong Long

Principal Investigator

Beijing Anzhen Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported